BUSINESSAug 4 · 17:41 UTCQUARTZCris Tolomia

Novo Nordisk is raising its full-year outlook as its weight loss pill keeps selling

Novo Nordisk is raising its full-year outlook due to strong sales of its weight loss pill Wegovy, which has surpassed 5 million prescriptions in the U.S., driving higher-than-expected profits.

Nexus surfaces and summarizes. The full story lives at the source.

Mentioned

Novo NordiskorganizationWegovytopicUnited Statesplace

Spot something wrong with this article?Report a problem →

Forward this

Related Signal

Adjacent reporting

BUSINESSMay 6 · 07:25 UTC
Novo Nordisk says the Wegovy pill saw the fastest take-up in weight-loss drug history
BUSINESSMay 6 · 13:34 UTC
STAT+: Novo Nordisk’s less-bad news on its Wegovy pill boosts earnings and share price
BUSINESSMay 6 · 06:46 UTC
Wegovy pill sales smash forecasts after launch as Novo Nordisk hikes guidance
HEALTHMay 18 · 05:00 UTC
Novo Nordisk’s next obesity battlefront: Winning beyond America
BUSINESSJul 3 · 15:08 UTC
Novo Nordisk is taking its new weight loss pill global
BUSINESSMay 6 · 06:18 UTC
Novo Raises Forecast as Wegovy Pill Fuels Sales